Dr. R J. White, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Pittsburgh School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 121
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Pittsburgh School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NY license 211627 -
Critical Care Medicine (Internal Medicine) Physician
NY license 211627
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- Highland Hospital Rochester, NY
- F F Thompson Hospital Canandaigua, NY
Medical groups
- Pulmonary Disease Clinical Group (68 clinicians)
- Mary M PArkes Asthma and Pulmonary (36 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 121
- Services billed
- 263
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 100 | 76 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 60 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 17 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tadalafil | 1,115 |
| Ambrisentan | 838 |
| Orenitram Er (treprostinil diolamine) | 224 |
| Spironolactone Other prescribers in Rochester, NY | 203 |
| Adempas (riociguat) | 161 |
| Torsemide Other prescribers in Rochester, NY | 161 |
| Tyvaso Dpi (treprostinil) | 154 |
| Jardiance (empagliflozin) Other prescribers in Rochester, NY | 127 |
| Winrevair (sotatercept-csrk) | 80 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Rochester, NY | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 78 payments worth $76,962 in total to this clinician.
| Merck Sharp & Dohme LLC | $75,580 |
|---|---|
| United Therapeutics Corporation | $1,328 |
| Sandoz Inc. | $53.74 |
| Travel and Lodging | $51,736 |
|---|---|
| Consulting Fee | $17,280 |
| Compensation for services other than consulting (speaking, faculty) | $5,850 |
| Food and Beverage | $2,096 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Mar 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Tremblay, France · in-kind | $15,709 |
| Merck Sharp & Dohme LLC Aug 22, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $8,738 |
| Merck Sharp & Dohme LLC Apr 12, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Zurich, Switzerland · in-kind | $8,374 |
| Merck Sharp & Dohme LLC Apr 28, 2025 | Travel and Lodging travel to Beijing, China · in-kind | $5,625 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Travel and Lodging travel to Shanghai, China · in-kind | $4,652 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,850 |
All 36 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| United Therapeutics Corporation Dec 7, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $297 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $688 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $221 |
| Merck Sharp & Dohme LLC Nov 12, 2025 | Consulting Fee | $1,280 |
| United Therapeutics Corporation Nov 11, 2025 | Travel and Lodging travel to Austin, TX · in-kind | $506 |
| Merck Sharp & Dohme LLC Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,850 |
| Merck Sharp & Dohme LLC Aug 22, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $8,738 |
| Merck Sharp & Dohme LLC Aug 22, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $1,283 |
| Merck Sharp & Dohme LLC Aug 22, 2025 | Travel and Lodging travel to Tokyo, Japan · in-kind | $493 |
| Merck Sharp & Dohme LLC Jun 11, 2025 | Travel and Lodging travel to Shanghai, China | $1,106 |
| Merck Sharp & Dohme LLC May 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Merck Sharp & Dohme LLC May 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Merck Sharp & Dohme LLC May 5, 2025 | Travel and Lodging travel to Shanghai, China | $150 |
| Merck Sharp & Dohme LLC Apr 28, 2025 | Travel and Lodging travel to Beijing, China · in-kind | $5,625 |
| Merck Sharp & Dohme LLC Apr 27, 2025 | Travel and Lodging travel to Beijing, China · in-kind | $525 |
| Merck Sharp & Dohme LLC Apr 27, 2025 | Travel and Lodging travel to Beijing, China · in-kind | $204 |
| Merck Sharp & Dohme LLC Apr 26, 2025 | Travel and Lodging travel to Shanghai, China · in-kind | $33.44 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Travel and Lodging travel to Shanghai, China · in-kind | $4,652 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Travel and Lodging travel to Shanghai, China · in-kind | $274 |
| Merck Sharp & Dohme LLC Apr 25, 2025 | Travel and Lodging travel to Shanghai, China · in-kind | $123 |
| Merck Sharp & Dohme LLC Apr 23, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Apr 14, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Apr 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Zurich, Switzerland · in-kind | $255 |
| Merck Sharp & Dohme LLC Apr 12, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Zurich, Switzerland · in-kind | $8,374 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $428 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $371 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $357 |
| Merck Sharp & Dohme LLC Apr 3, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Boston, MA · in-kind | $173 |
| Merck Sharp & Dohme LLC Mar 26, 2025 | Consulting Fee | $4,000 |
| Merck Sharp & Dohme LLC Mar 16, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Tremblay, France · in-kind | $174 |
| Merck Sharp & Dohme LLC Mar 15, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Tremblay, France · in-kind | $157 |
| Merck Sharp & Dohme LLC Mar 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Tremblay, France · in-kind | $15,709 |
| Merck Sharp & Dohme LLC Mar 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Tremblay, France · in-kind | $306 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $592,165 in research payments for these studies, mostly to the institutions running them.
- An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH
Merck Sharp & Dohme LLC - A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Hea…
Merck Sharp & Dohme LLC - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension PAH World Health Organizati…
Merck Sharp & Dohme LLC - A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510 - A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
United Therapeutics Corporation · Completed · NCT03626688
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.